10-Q: Coeptis Therapeutics Holdings Reports First Quarter 2024 Results Amidst Ongoing Development Efforts

Coeptis Therapeutics Holdings reported a net loss of $3.0 million for the first quarter of 2024, while continuing to advance its cell therapy technologies.

Summary

• Coeptis Therapeutics Holdings reported a net loss of $3,001,388 for the three months ended March 31, 2024, compared to a net loss of $7,957,833 for the same period in 2023.
• The company's operating expenses decreased to $2,922,383 in Q1 2024 from $6,538,951 in Q1 2023, primarily due to lower professional services expenses.
• Cash and cash equivalents decreased to $1,029,244 as of March 31, 2024, from $1,469,134 at the end of 2023.
• The company continues to focus on developing its cell therapy technologies, including CD38-GEAR-NK and CD38-Diagnostic, and has expanded its license agreement with the University of Pittsburgh.
• Coeptis has also entered into a licensing arrangement with Deverra Therapeutics, acquiring key patents and assets related to allogeneic stem cell expansion.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the company's research and development efforts and a reduction in operating expenses, the significant net loss, decreasing cash reserves, and defaults on notes payable raise concerns about the company's financial stability and ability to continue as a going concern. The ineffective disclosure controls and procedures also add to the negative sentiment.

Positives

• The net loss decreased significantly year-over-year, indicating improved financial performance.
• Operating expenses were substantially reduced, reflecting cost management efforts.
• The company is actively developing its cell therapy technologies and expanding its intellectual property portfolio.
• The company has secured key licensing agreements and partnerships to advance its therapeutic programs.

Negatives

• The company continues to experience net losses, indicating ongoing financial challenges.
• Cash reserves have decreased, raising concerns about the company's liquidity.
• Several notes payable are in default, indicating potential financial instability.
• The company's disclosure controls and procedures were not operating effectively.

Risks

• The company has an accumulated deficit of $90,357,648 and a net loss of $3,001,388 for the quarter, raising substantial doubt about its ability to continue as a going concern.
• The company's ability to obtain sufficient financing or establish itself as a profitable business is uncertain.
• Several notes payable are in default, which could lead to further financial difficulties.
• The company's disclosure controls and procedures were not operating effectively, indicating potential internal control weaknesses.
• The company is dependent on raising additional capital through sales of equity or debt securities to pursue its business plans.

Future Outlook

The company expects to continue focusing on product development, raising capital, and building infrastructure. Management anticipates that general and administrative expenses will increase as the company grows and incurs additional costs associated with operating as a public company. The company also expects research and development costs to increase to support new strategic initiatives.

Management Comments

• Management believes that additional financing as necessary will result in improved operations and cash flow.
• Management does not expect the Company to generate any significant revenue for at least the next two years, during which time drug development will continue toward the goal of commercializing, through a partnership or otherwise, one or more of the Company's target products or technologies.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on cell therapy technologies for cancer and other diseases. The company's focus on innovative products and technologies aligns with the broader industry trend of developing novel therapies for unmet medical needs. The company's partnerships and licensing agreements are also common strategies in the industry to accelerate development and commercialization.

Comparison to Industry Standards

• Coeptis's financial performance, with a net loss of $3.0 million in Q1 2024, is not uncommon for early-stage biopharmaceutical companies focused on research and development. For example, companies like Cellectis and Bellicum Pharmaceuticals, which are also developing cell therapies, have reported similar losses in their early stages.
• The company's operating expenses of $2.9 million in Q1 2024 are relatively low compared to larger biopharma companies, reflecting its focus on early-stage development and strategic partnerships. Companies like Kite Pharma and Juno Therapeutics, which have more advanced clinical programs, have significantly higher operating expenses.
• Coeptis's cash position of $1.0 million is relatively low compared to industry standards, highlighting the need for additional capital raises. Companies with more advanced clinical programs typically have larger cash reserves to fund their operations and clinical trials.
• The company's focus on CD38-GEAR-NK and CD38-Diagnostic aligns with the industry's interest in developing targeted therapies for multiple myeloma and other CD38-related cancers. Companies like Janssen and Bristol Myers Squibb have also invested heavily in this area.
• Coeptis's licensing agreements with the University of Pittsburgh and Deverra Therapeutics are common strategies in the industry to access innovative technologies and intellectual property. Many biopharma companies, such as Gilead and Regeneron, have used similar strategies to expand their pipelines.

Related Party Transactions

• In September 2023, the Company entered into a transaction with AG Bio Life Capital I LP (AG), a Delaware limited partnership, where an employee of the Company is the general partner.
• On April 17, 2024, the Company entered into an unsecured note agreement with a related party in the principal amount of $500,000 together with interest at 10%, which is due on September 30, 2024. The agreement is between the Company and an investment fund where the manager is a member of the Company's board of directors.

Stakeholder Impact

• Shareholders are impacted by the company's net losses and decreasing cash reserves, which could affect the value of their investments.
• Employees are impacted by the company's financial challenges, which could affect job security and compensation.
• Customers and partners are impacted by the company's ability to develop and commercialize its products, which could affect the availability of new therapies.
• Creditors are impacted by the company's defaults on notes payable, which could affect their ability to recover their investments.

Next Steps

• The company will continue to focus on product development, raising capital, and building infrastructure.
• The company will continue to explore partnership opportunities with companies that have novel therapies.
• The company will continue to assess market opportunities, intellectual property protection, and potential regulatory strategies for the CD38 Assets.
• The company will continue to collaborate with Deverra to further the development of Coeptis GEAR and SNAP-CAR platforms.

Key Dates

Keywords

cell therapy, oncology, CD38, GEAR-NK, SNAP-CAR, biopharmaceutical, warrants, licensing, clinical trials, stem cell